{"id":36055,"date":"2024-08-22T13:06:50","date_gmt":"2024-08-22T11:06:50","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=36055"},"modified":"2024-08-21T12:10:43","modified_gmt":"2024-08-21T10:10:43","slug":"colchicin-in-der-rezidivprophylaxe-bei-kleinen-bis-mittelschweren-akuten-schlaganfaellen-cme","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2024\/colchicin-in-der-rezidivprophylaxe-bei-kleinen-bis-mittelschweren-akuten-schlaganfaellen-cme","title":{"rendered":"Colchicin in der Rezidivprophylaxe bei kleinen bis mittelschweren akuten Schlaganf\u00e4llen [CME]"},"content":{"rendered":"<p>Schlaganf\u00e4lle werden nach ihrer Pathogenese in f\u00fcnf Subtypen differenziert (TOAST-Klassifikation;\u00a0): Arteriosklerose der gro\u00dfen Arterien; Kardioembolie; Verschluss kleiner Gef\u00e4\u00dfe; Schlaganfall mit ungew\u00f6hnlicher anderer, definierter \u00c4tiologie (z.B. Dissektionen, fibromuskul\u00e4re Dysplasie, Vaskulitis u.a.; Schlaganfall unbestimmter \u00c4tiologie (ESUS = Embolic Stroke of Undetermined Source). Etwa 25% der Patienten mit akutem isch\u00e4mischem Insult sind im Verlauf von einem Rezidiv betroffen, [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Schlaganf\u00e4lle werden nach ihrer Pathogenese in f\u00fcnf Subtypen differenziert (TOAST-Klassifikation;\u00a0): Arteriosklerose der gro\u00dfen Arterien; Kardioembolie; Verschluss kleiner Gef\u00e4\u00dfe; Schlaganfall mit ungew\u00f6hnlicher anderer, definierter \u00c4tiologie (z.B. Dissektionen, fibromuskul\u00e4re Dysplasie, Vaskulitis u.a.; Schlaganfall unbestimmter \u00c4tiologie (ESUS = Embolic Stroke of Undetermined Source). Etwa 25% der Patienten mit akutem isch\u00e4mischem Insult sind im Verlauf von einem Rezidiv betroffen, [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[60,1272,6062,285,6063,68,56,3140],"class_list":["post-36055","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-apoplektischer-insult","tag-arteriosklerose","tag-chance-3-studie","tag-colchicin","tag-convince-studie","tag-hirninfarkt","tag-schlaganfall","tag-transitorische-ischaemische-attacke"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/36055","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=36055"}],"version-history":[{"count":1,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/36055\/revisions"}],"predecessor-version":[{"id":36056,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/36055\/revisions\/36056"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=36055"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=36055"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=36055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}